{"nctId":"NCT01237223","briefTitle":"Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension","startDateStruct":{"date":"2010-10"},"conditions":["Essential Hypertension"],"count":1342,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo of Aliskiren","Drug: Placebo of Amlodipine","Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg","Drug: Placebo of Aliskiren/amlodipine 150/5 mg"]},{"label":"Aliskiren 150 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aliskiren 150 mg","Drug: Placebo of Amlodipine","Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg","Drug: Placebo of Aliskiren/amlodipine 150/5 mg"]},{"label":"Amlodipine 2.5 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Amlodipine 2.5 mg","Drug: Placebo of Aliskiren","Drug: Placebo of Amlodipine","Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg","Drug: Placebo of Aliskiren/amlodipine 150/5 mg"]},{"label":"Amlodipine 5 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Amlodipine 2.5 mg","Drug: Placebo of Aliskiren","Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg","Drug: Placebo of Aliskiren/amlodipine 150/5 mg"]},{"label":"Aliskiren/amlodipine 150/2.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren/Amlodipine 150/2.5 mg","Drug: Placebo of Aliskiren","Drug: Placebo of Amlodipine","Drug: Placebo of Aliskiren/amlodipine 150/5 mg"]},{"label":"Aliskiren/amlodipine 150/5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren/amlodipine 150/5 mg","Drug: Placebo of Aliskiren","Drug: Placebo of Amlodipine","Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg"]}],"interventions":[{"name":"Aliskiren/Amlodipine 150/2.5 mg","otherNames":[]},{"name":"Aliskiren/amlodipine 150/5 mg","otherNames":[]},{"name":"Aliskiren 150 mg","otherNames":[]},{"name":"Amlodipine 2.5 mg","otherNames":[]},{"name":"Placebo of Aliskiren","otherNames":[]},{"name":"Placebo of Amlodipine","otherNames":[]},{"name":"Placebo of Aliskiren/amlodipine 150/2.5 mg","otherNames":[]},{"name":"Placebo of Aliskiren/amlodipine 150/5 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with essential hypertension (msDBP ≥ 95 mmHg and \\< 110 mmHg and msSBP ≥140 mmHg )\n* Outpatients\n\nExclusion Criteria:\n\n* Severe hypertension (msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg)\n* History of allergy or hypersensitivity to renin inhibitors, calcium channel blockers\n* History or evidence of a secondary hypertension\n\nOther protocol-defined inclusion/exclusion criteria applied","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8)","description":"Sitting blood pressure was measured at trough (24 hours ± 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.21","spread":"0.69"},{"groupId":"OG001","value":"-7.49","spread":"0.68"},{"groupId":"OG002","value":"-9.46","spread":"0.68"},{"groupId":"OG003","value":"-11.90","spread":"0.68"},{"groupId":"OG004","value":"-12.40","spread":"0.68"},{"groupId":"OG005","value":"-16.43","spread":"0.68"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) to End of Study (Week 8)","description":"Sitting blood pressure was measured at trough (24 hours ± 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.57","spread":"0.97"},{"groupId":"OG001","value":"-10.63","spread":"0.96"},{"groupId":"OG002","value":"-13.16","spread":"0.96"},{"groupId":"OG003","value":"-17.98","spread":"0.96"},{"groupId":"OG004","value":"-18.15","spread":"0.96"},{"groupId":"OG005","value":"-25.49","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Blood Pressure Control at Endpoint","description":"Blood pressure control is defined as having as a msDBP \\< 90 mmHg and a msSBP \\< 140 mmHg.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"25.5","spread":null},{"groupId":"OG002","value":"32.9","spread":null},{"groupId":"OG003","value":"50.0","spread":null},{"groupId":"OG004","value":"45.9","spread":null},{"groupId":"OG005","value":"69.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Successful Response Rate","description":"The response rate was defined as percentage of participants who achieved msDBP \\< 90 mmHg or its reduction ≥ 10 mmHg from baseline to endpoint.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6","spread":null},{"groupId":"OG001","value":"46.5","spread":null},{"groupId":"OG002","value":"50.6","spread":null},{"groupId":"OG003","value":"70.3","spread":null},{"groupId":"OG004","value":"65.4","spread":null},{"groupId":"OG005","value":"86.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events, Serious Adverse Events and Death","description":"Number of patients with adverse events regardless of study drug relationship during the double-blind treatment period were reported. Serious adverse events of double blind period were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"50","spread":null},{"groupId":"OG003","value":"49","spread":null},{"groupId":"OG004","value":"57","spread":null},{"groupId":"OG005","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":153},"commonTop":["Nasopharyngitis","Headache"]}}}